Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timo Joensuu

Showing results (11-20 of 67) with videos related to

Pageof 7
Sort By:
World Journal of Gastroenterology|June 26, 2007
Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancerPälvi Vento, Harri Mustonen, Timo Joensuu, et al.
Ophthalmology|October 3, 2003
Stereotactic radiotherapy of symptomatic circumscribed choroidal hemangiomasTero Kivelä, Mikko Tenhunen, Timo Joensuu, et al.
Life (Basel, Switzerland)|December 23, 2022
A Retrospective Comparative Study of Sodium Fluoride Na<sup>18</sup>F-PET/CT and <sup>68</sup>Ga-PSMA-11 PET/CT in the Bone Metastases of Prostate Cancer Using a Volumetric 3-D Radiomic AnalysisKalevi Kairemo, Aki Kangasmäki, Srinivasan Cheenu Kappadath, et al.
Current Radiopharmaceuticals|April 18, 2015
PET/CT Dose Planning for Volumetric Modulated Arc Radiation Therapy (VMAT) -Comparison with Conventional Approach in Advanced Prostate Cancer PatientsKalevi Kairemo, Nigora Rasulova, Timo Kiljunen, et al.
Oncotarget|October 15, 2017
<sup>177</sup>Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancerFinn E von Eyben, Timo Kiljunen, Timo Joensuu, et al.
Acta Oncologica (Stockholm, Sweden)|December 14, 2011
A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapyGreetta Joensuu, Timo Joensuu, Nina Nupponen, et al.
International Journal of Radiation Oncology, Biology, Physics|September 19, 2015
Volumetric Modulated Arc Therapy Planning For Primary Prostate Cancer With Selective Intraprostatic Boost Determined By (18) f-Choline PET-CT: In Regard to Kuang et alFinn Edler von Eyben, Timo Kiljunen, Aki Kangasmaki, et al.
Clinical Genitourinary Cancer|January 16, 2016
Radiotherapy Boost for the Dominant Intraprostatic Cancer Lesion-A Systematic Review and Meta-AnalysisFinn Edler von Eyben, Timo Kiljunen, Aki Kangasmaki, et al.
Cancers|December 23, 2022
Single Center Experience with a 4-Week <sup>177</sup>Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate CancerJukka Kemppainen, Aki Kangasmäki, Simona Malaspina, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 17, 2017
Third-line treatment and <sup>177</sup>Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic reviewFinn Edler von Eyben, Giandomenico Roviello, Timo Kiljunen, et al.
Pageof 7

Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
World Journal of Gastroenterology|June 26, 2007
Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancerPälvi Vento, Harri Mustonen, Timo Joensuu, et al.
Ophthalmology|October 3, 2003
Stereotactic radiotherapy of symptomatic circumscribed choroidal hemangiomasTero Kivelä, Mikko Tenhunen, Timo Joensuu, et al.
Life (Basel, Switzerland)|December 23, 2022
A Retrospective Comparative Study of Sodium Fluoride Na<sup>18</sup>F-PET/CT and <sup>68</sup>Ga-PSMA-11 PET/CT in the Bone Metastases of Prostate Cancer Using a Volumetric 3-D Radiomic AnalysisKalevi Kairemo, Aki Kangasmäki, Srinivasan Cheenu Kappadath, et al.
Current Radiopharmaceuticals|April 18, 2015
PET/CT Dose Planning for Volumetric Modulated Arc Radiation Therapy (VMAT) -Comparison with Conventional Approach in Advanced Prostate Cancer PatientsKalevi Kairemo, Nigora Rasulova, Timo Kiljunen, et al.
Oncotarget|October 15, 2017
<sup>177</sup>Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancerFinn E von Eyben, Timo Kiljunen, Timo Joensuu, et al.
Acta Oncologica (Stockholm, Sweden)|December 14, 2011
A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapyGreetta Joensuu, Timo Joensuu, Nina Nupponen, et al.
International Journal of Radiation Oncology, Biology, Physics|September 19, 2015
Volumetric Modulated Arc Therapy Planning For Primary Prostate Cancer With Selective Intraprostatic Boost Determined By (18) f-Choline PET-CT: In Regard to Kuang et alFinn Edler von Eyben, Timo Kiljunen, Aki Kangasmaki, et al.
Clinical Genitourinary Cancer|January 16, 2016
Radiotherapy Boost for the Dominant Intraprostatic Cancer Lesion-A Systematic Review and Meta-AnalysisFinn Edler von Eyben, Timo Kiljunen, Aki Kangasmaki, et al.
Cancers|December 23, 2022
Single Center Experience with a 4-Week <sup>177</sup>Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate CancerJukka Kemppainen, Aki Kangasmäki, Simona Malaspina, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 17, 2017
Third-line treatment and <sup>177</sup>Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic reviewFinn Edler von Eyben, Giandomenico Roviello, Timo Kiljunen, et al.
Pageof 7